Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: epratuzumab, Immunomedics/Amgen.

Malik Juweid1

  • 1Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. malik-juweid@uiowa.edu

Current Opinion in Molecular Therapeutics
|May 30, 2003
PubMed
Summary

Epratuzumab, an anti-CD22 antibody, is being developed for lymphoma and autoimmune diseases. It has received Orphan Drug status for non-Hodgkin's lymphoma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronotherapy in head and neck cancer: A systematic review and meta-analysis.

International journal of cancer·2024
Same author

The transformation of Jordan's healthcare system in an area of conflict.

BMC health services research·2024
Same author

An Overview of Appropriate Medical Practice and Preparedness in Radiation Emergency Response.

Cureus·2024
Same author

Admission criteria and academic performance in medical school.

BMC medical education·2023
Same author

The Preventable Effect of Taekwondo Sport among Cadets and Junior' Bone Mineral Density: DEXA Assessment.

Children (Basel, Switzerland)·2023
Same author

Children with Hirschsprung disease in a developing country: A cohort study of the predictors of a positive rectal biopsy result.

Medicine·2022

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies are a growing class of therapeutics.
  • CD22 is a target antigen expressed on B-cells, making it a potential target for B-cell malignancies and autoimmune diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of epratuzumab in patients with lymphoma and autoimmune conditions.
  • To explore the potential of epratuzumab as a targeted therapy for B-cell malignancies.

Main Methods:

  • Development of unconjugated and radioisotope-linked (90Y) forms of epratuzumab.
  • Phase III clinical trials for aggressive lymphoma.
  • Orphan Drug designation for non-Hodgkin's lymphoma (NHL).

Main Results:

  • Epratuzumab is under investigation in Phase III trials for aggressive lymphoma.
  • Orphan Drug status granted for NHL treatment potential.
  • Dual development tracks: unconjugated and radioisotope-linked forms.

Conclusions:

  • Epratuzumab shows promise as a targeted therapy for lymphoma and autoimmune diseases.
  • Further clinical trials are necessary to establish its efficacy and safety profile.
  • The development of epratuzumab represents a significant advancement in targeted cancer therapy.

Related Experiment Videos